NDAINTRAVENOUSSOLUTION
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NEURACEQ (florbetaben f 18) by Remedy Plan Therapeutics is positron emitting activity [moa]. First approved in 2014.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEURACEQ (florbetaben F-18) is an intravenous radioactive diagnostic agent that uses positron-emitting activity to detect amyloid pathology in the brain. It is indicated for PET imaging to assess amyloid burden in patients with cognitive impairment suspected of having Alzheimer's disease or related neurodegeneration. The drug enables non-invasive visualization of amyloid-beta accumulation, a hallmark pathological feature of Alzheimer's disease.
Peak5.7 years to LOE
Peak-stage product with no direct competitors in the amyloid PET imaging space, suggesting stable commercial operations but limited growth opportunities and potential team consolidation as lifecycle matures.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEURACEQ represents a stable, low-growth career assignment suitable for professionals seeking deep expertise in diagnostic oncology/neurology markets and reimbursement strategy. Career progression is constrained by narrow indication scope and absence of active development pipeline, making this best suited for mid-career specialists rather than high-growth trajectory roles.
Product Manager / Brand Manager
Worked on NEURACEQ at Remedy Plan Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.